Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.49 |
| ▸ | STRADA | Q7RTN6 | 1/20 | 0.49 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6501247 | 0.97 | MAPK14 (0.50) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL6473916 | 0.93 | MAPK14 (0.49) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL6471438 | 0.92 | MAPK14 (0.59) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL6472178 | 0.90 | MAPK14 (0.51) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL6499905 | 0.90 | MAPK14 (0.59) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL6472316 | 0.89 | MAPK14 (0.61) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL6508489 | 0.87 | MAPK14 (0.44) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL6506921 | 0.86 | MAPK14 (0.50) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL6470892 | 0.85 | MAPK14 (0.49) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL4385571 | 0.84 | MAPK14 (0.45) | MAPK14MAPK11ROCK2MAPK12STRADA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176775-A1 | Substituted pyridinones | PHARMACIA CORPORATION | 2005-08-11 | — | — | US | claimed |
| US-20050176775-A1 | Substituted pyridinones | PHARMACIA CORPORATION | 2005-08-11 | — | — | US | disclosed |
| WO-2005018557-A2 | SUBSTITUTED PYRIDINONES | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176775-A1 | Substituted pyridinones | MAPK1, MAPK6, MAP3K6 | MAPK14 53/4885MAPK11 84/4885ROCK2 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.